ReportWire

Tag: Ohio State University Wexner Medical Center

  • fMRI study finds correlated shifts in brain connectivity associated with overthinking in adolescents

    fMRI study finds correlated shifts in brain connectivity associated with overthinking in adolescents

    [ad_1]

    Newswise — COLUMBUS, Ohio – A new study from The Ohio State University Wexner Medical Center and College of Medicine, University of Utah and University of Exeter (UK) substantiates previous groundbreaking research that rumination (overthinking) can be reduced through an intervention called Rumination-focused Cognitive Behavioral Therapy (RF-CBT). In addition, the use of fMRI technology allowed researchers to observe correlated shifts in the brain connectivity associated with overthinking.

    Study findings are published online in the journal Biological Psychiatry Global Open Science.

    “We know adolescent development is pivotal. Their brains are maturing, and habits are forming. Interventions like RF-CBT can be game-changers, steering them towards a mentally healthy adulthood. We were particularly excited that the treatment seemed developmentally appropriate and was acceptable and accessible via telehealth during the early pandemic,” said corresponding author Scott Langenecker, PhD, vice chair of research in the Department of Psychiatry and Behavioral Health at Ohio State, who started this project while at the University of Utah.

    RF-CBT is a promising approach pioneered by Ed Watkins, PhD, professor of experimental and applied Clinical Psychology at the University of Exeter. It has been shown to be effective among adults with recurrent depression.

    “We wanted to see if we could adapt it for a younger population to prevent the ongoing burden of depressive relapse,” said Rachel Jacobs, PhD, adjunct assistant professor of psychiatry and behavioral sciences at Northwestern University who conducted the pilot study in 2016.

    “As a clinician, I continued to observe that standard CBT tools such as cognitive restructuring didn’t give young people the tools to break out of the painful mental loops that contribute to experiencing depression again. If we could find a way to do that, maybe we could help young people stay well as they transition to adulthood, which has become even more important since we’ve observed the mental health impact of COVID-19,” Jacobs said.

    In the just published trial, 76 teenagers, ages 14-17, with a history of depression were randomly assigned to 10-14 sessions of RF-CBT, while controls were allowed and encouraged to receive any standard treatment. Teens reported ruminating significantly less if they received RF-CBT. Even more intriguing, fMRI illustrated shifts in brain connectivity, marking a change at the neural level.

    Specifically, there was a reduction in the connection between the left posterior cingulate cortex and two other regions; the right inferior frontal gyrus and right inferior temporal gyrus. These zones, involved in self-referential thinking and emotional stimuli processing, respectively, suggest RF-CBT can enhance the brain’s ability to shift out of the rumination habit. Notably, this work is a pre-registered replication; it demonstrates the same brain and clinical effects in the Utah sample in 2023 that was first reported in the Chicago sample in 2016.

    “For the first time, this paper shows that the version of rumination-focused CBT we have developed at the University of Exeter leads to changes in connectivity in brain regions in adolescents with a history of depression relative to treatment as usual. This is exciting, as it suggests the CBT either helps patients to gain more effortless control over rumination or makes it less habitual. We urgently need new ways to reduce rumination in this group in order to improve the mental health of our young people,” Watkins said.

    Next, the researchers will focus on demonstrating the efficacy of RF-CBT in a larger sample with an active treatment control, including continued work at Ohio State, Nationwide Children’s Hospital, University of Exeter, University of Utah and the Utah Center for Evidence Based Treatment. Future directions include bolstering access to teens in clinical settings and enhancing the ways we can learn about how this treatment helps youth with similar conditions.

    “Our paper suggests a science-backed method to break the rumination cycle and reinforces the idea that it’s never too late or too early to foster healthier mental habits. Our research team thanks the youths and families who participated in this study for their commitment and dedication to reducing the burden of depression through science and treatment, particularly during the challenges of a global pandemic,” Langenecker said.

    This work was supported by the National Institutes of Mental Health and funds from the Huntsman Mental Health Institute and is dedicated to researcher Kortni K. Meyers and others who have lost their lives to depression.

     # # #

    [ad_2]

    Ohio State University Wexner Medical Center

    Source link

  • Study explores how community engagement can help improve clinical trial diversity

    Study explores how community engagement can help improve clinical trial diversity

    [ad_1]

    Newswise — COLUMBUS, Ohio – Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc. and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism and workforce diversity.

    Study findings are published online in the journal PLOS One.

    “Equitable representation is key when testing novel therapeutic and non-therapeutic interventions to ensure safety and effectiveness across populations, especially since 20% of new drugs demonstrate differences in exposure and/or response across racial and ethnic groups,” said senior author Dr. Joshua Joseph, assistant professor of medicine in the Division of Endocrinology, Diabetes and Metabolism and an investigator in the Diabetes & Metabolism Research Center.

    “The lack of Black and Hispanic/Latinx populations in clinical research studies for endocrine conditions including diabetes, cancer, and cardiovascular disease research is particularly troubling because these diseases are common with a high prevalence and mortality in racial and ethnic minority populations,” said co-author Timiya Nolan, assistant professor of nursing and principal investigator of Partners in Negating Statistics in Black Women (PINS).

    During the study in 2021, participants attended two webinars in a four-part series titled “Health Equity Through Diversity: From Communities to Clinics to Clinical Trials.” They discussed solutions for advancing health equity through diversifying clinical trials and addressing medical mistrust in communities.

    Each 90-minute webinar began with panelist discussions followed by breakout rooms where moderators led discussions related to health equity while scribes recorded the conversations. The diverse groups of panelists included community members, civic representatives, clinician-scientists, government organizations and biotechnology/biopharmaceutical professionals. Scribe notes from discussions were collected and thematically analyzed to uncover the central themes.

    “We found that based on these discussions, barriers to clinical trial participation were broadly grouped into the themes of access, awareness, discrimination and racism and workforce diversity. Participants noted that innovative, community-engaged, co-designed solutions are essential,” said first author Luiza Reopell, clinical study coordinator with the Division of Endocrinology, Diabetes and Metabolism.

    Within each theme, barriers and solutions to clinical trial participation were identified:

    • Access: Barriers included opportunity cost, transportation, caregiver burden and work. Solutions included transportation vouchers and extending clinic hours.
    • Awareness: Barriers included contact with healthcare system, research literacy, language and health literacy. Solutions included using translators or research ambassadors and educating patients.
    • Racism: Barriers included interpersonal, structural and institutional racism. Solutions included investing in communities and offering training for providers.
    • Workforce Diversity: Barriers included lack of coordination and lack of clinical research coordinator diversity. Solutions included hiring racially and ethnically diverse staff and ensuring cultural competence.

    Study collaborators included researchers at Ohio State’s College of Nursing, College of Public Health; and Center for Clinical and Translational Science; the Center for Cancer Health Equity at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; the Mayo Clinic College of Medicine; The University of North Carolina at Chapel Hill School of Nursing; Franklin University; Hue-Man Partnership and the National Center for Urban Solutions.

    Funding for this study includes the National Institute of Diabetes and Digestive and Kidney Diseases and the Robert Wood Johnson Foundation. Genentech, Inc. and Pfizer, Inc. provided financial support for the webinar series. The Center for Primary Care Innovation and Transformation at Ohio State Wexner Medical Center and Ohio State College of Nursing provided logistical and technical support with producing the webinar series.

    # # #

    [ad_2]

    Ohio State University Wexner Medical Center

    Source link